Black Book Research and Applied Artificial Intelligence LLC identify 2026-2027 client-rated technology leaders across 28 pharmaceutical, biotechnology and life sciences markets based on 1,277 verified buyers and users
CHICAGO, IL / ACCESS Newswire / August 10, 2026 / Black Book Research today published the 2026-2027 Life Sciences AI Technology Performance Benchmark, developed with research partner and contributing author Applied Artificial Intelligence LLC. Based on 1,277 verified buyers, scientific and operational leaders, technical evaluators and direct users, the independent study evaluates 254 market participants across 28 categories and scorecards.
The benchmark spans the molecule-to-market lifecycle, including target discovery, generative chemistry, protein and antibody design, multi-omics, clinical development, real-world evidence, pharmacovigilance, regulatory operations, scientific-data infrastructure, GxP manufacturing, quality, supply chain, medical affairs, commercial execution and enterprise AI governance.
Its central finding is that life sciences buyers are moving beyond model novelty and isolated proofs of concept. They now expect AI-enabled systems to operate within validated workflows, maintain data and model lineage, integrate with regulated systems, support human authorization and deliver measurable scientific, clinical or operating value.
"Life sciences AI is entering a governed production era in which the differentiator is no longer model sophistication in isolation," said Vasyl Harasymiv, founder of Applied Artificial Intelligence LLC and research partner to Black Book Research. "Sponsors, biopharma manufacturers, CROs, CDMOs and translational-research networks are testing whether platforms can combine multimodal data fidelity, prospective validation within a defined context of use, reproducible and uncertainty-aware outputs, controlled model change and audit-ready human oversight."
"Durable value will come from systems that compress design-make-test-learn cycles, improve protocol feasibility and evidence generation, strengthen safety and submission operations, raise process yield and batch-release confidence, and protect continuity across clinical supply and commercial manufacturing," Harasymiv added.
2027 Outlook: Five Market Signals
AI investment is concentrating around five connected layers: evidence generation, clinical operations, AI-ready data foundations, regulated manufacturing and quality, and enterprise AI governance.
RWE is separating into distinct purchasing markets for self-service analytics, privacy-preserving linkage and tokenization, external controls, and HEOR and market-access evidence strategy.
Agentic AI is advancing first through bounded, reversible and human-approved workflows, rather than autonomous regulated decisions. Reconstructable actions, approval gates and accountable human intervention remain essential.
Manufacturing, quality and supply-chain AI are gaining executive attention because value can be measured through yield, cycle time, deviation reduction, batch review, inventory, shortage risk, cold-chain performance and chain-of-identity integrity.
GxP validation, continuous monitoring and model-change control are becoming formal selection criteria as sponsors consolidate redundant point solutions while retaining specialist platforms that demonstrate superior outcomes.
Q3 2026 Category Leaders
Discovery and preclinical leaders include Insilico Medicine, Schrödinger, Generate Biomedicines, Tempus AI, Clarivate Cortellis and Certara.
Clinical-development and evidence leaders include Medidata, Tempus AI/Deep 6 AI, CluePoints, ActiGraph, Veradigm, Datavant/Aetion and IQVIA.
Safety, regulatory, data and diagnostics leaders include ArisGlobal, Veeva, InterSystems, DNAnexus, PathAI and Siemens, including Dotmatics.
Manufacturing, quality and supply-chain leaders include Siemens, Veeva, Kinaxis and Controlant.
Veeva Medical, Veeva Vault CRM/Nitro, SAS and Accenture lead medical affairs, commercial technology, AI governance and life sciences consulting, respectively.
Black Book applies an 18-KPI performance framework covering scientific and clinical outcomes, data provenance, interoperability, implementation, regulatory and GxP readiness, explainability, auditability, service performance and demonstrated return on investment. Recognition applies only to the evaluated product, platform or service within its defined purchasing category. Vendors cannot purchase inclusion or rank position, and prior-year recognition does not transfer automatically.
The complete report is available to industry stakeholders at: https://blackbookmarketresearch.com/ai-enabled-healthcare-technology-platforms-software-and-services
About Black Book Research
Black Book Research is an independent healthcare and life sciences market intelligence organization that has supported life sciences, biomedical, pharmaceutical development and manufacturing organizations for more than two decades. Since 2004, through role-qualified client feedback and vendor-neutral competitive intelligence, Black Book evaluates technology vendors, software and data platforms, consultants, systems integrators, managed-service firms and specialized scientific partners across the molecule-to-market continuum, from discovery and clinical development through RWE, safety, regulatory operations, laboratories, GxP manufacturing, quality, supply chain, medical affairs and commercialization. Its research helps executives, investors, scientific leaders, manufacturers, CROs and CDMOs assess performance, regulatory readiness, service quality, measurable value and long-term partner fit.
About Applied Artificial Intelligence LLC
Applied Artificial Intelligence LLC is a Chicago-based financial and technology advisory firm founded by Vasyl Harasymiv. The firm brings cross-sector expertise spanning financial markets, banking, venture capital, investment organizations, healthcare, life sciences, biomedical innovation, and pharmaceutical development and manufacturing. Applied Artificial Intelligence LLC advises investors, boards, executives and operating teams on AI strategy, financial and technology due diligence, capital allocation, enterprise architecture, governance, risk management, implementation and measurable value realization.
The firm also provides interim and temporary leadership for organizations navigating AI evaluation, deployment, transformation and operational transition. By combining financial-market discipline with technical and regulated-industry expertise, Applied Artificial Intelligence LLC helps organizations convert AI initiatives into governed, operationally credible and financially accountable programs.
Media Contact
research@blackbookmarketresearch.com
1.800.863.7590
SOURCE: Black Book Research
View the original press release on ACCESS Newswire